{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T02:17:59Z","timestamp":1769307479729,"version":"3.49.0"},"reference-count":167,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T00:00:00Z","timestamp":1444694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/igo\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["2011 53 05"],"award-info":[{"award-number":["2011 53 05"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["2010 53 04"],"award-info":[{"award-number":["2010 53 04"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["2007IARC01"],"award-info":[{"award-number":["2007IARC01"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008700","name":"International Agency for Research on Cancer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008700","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["cancerepidemiology.net","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.canep.2015.10.006","type":"journal-article","created":{"date-parts":[[2015,11,15]],"date-time":"2015-11-15T02:43:22Z","timestamp":1447555402000},"page":"S120-S138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"S1","title":["European Code against Cancer 4th Edition: Infections and Cancer"],"prefix":"10.1016","volume":"39","author":[{"given":"Patricia","family":"Villain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maribel","family":"Almonte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Franceschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joakim","family":"Dillner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahti","family":"Anttila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"De Vuyst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolando","family":"Herrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canep.2015.10.006_bib0005","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1470-2045(12)70137-7","article-title":"Global burden of cancers attributable to infections in 2008: a review and synthetic analysis","volume":"13","author":"De Martel","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canep.2015.10.006_bib0010","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canep.2015.10.006_bib0015","unstructured":"IARC, Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 100B: A Review of Human Carcinogens: Biological Agents, (2012)."},{"issue":"Suppl. 5","key":"10.1016\/j.canep.2015.10.006_bib0020","doi-asserted-by":"crossref","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of human papillomavirus and related diseases","volume":"30","author":"Forman","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.canep.2015.10.006_bib0025","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ijc.25396","article-title":"Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication","volume":"128","author":"Li","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canep.2015.10.006_bib0030","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1016\/j.ejca.2014.07.018","article-title":"Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples","volume":"50","author":"Alemany","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canep.2015.10.006_bib0035","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.28963","article-title":"Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide","volume":"136","author":"Alemany","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canep.2015.10.006_bib0040","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jcp.2008.063149","article-title":"Human papillomavirus prevalence and type distribution in penile carcinoma","volume":"62","author":"Miralles-Guri","year":"2009","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.canep.2015.10.006_bib0045","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/jnci\/djg107","article-title":"Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study","volume":"95","author":"Herrero","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"issue":"Suppl. 5","key":"10.1016\/j.canep.2015.10.006_bib0050","doi-asserted-by":"crossref","first-page":"F34","DOI":"10.1016\/j.vaccine.2012.05.070","article-title":"Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis","volume":"30","author":"Gillison","year":"2012","journal-title":"Vaccine"},{"issue":"Suppl. 5","key":"10.1016\/j.canep.2015.10.006_bib0055","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1016\/j.vaccine.2012.05.090","article-title":"Reframing cervical cancer prevention. Expanding the field towards prevention of human papillomavirus infections and related diseases","volume":"30","author":"Bosch","year":"2012","journal-title":"Vaccine"},{"issue":"Suppl. 3","key":"10.1016\/j.canep.2015.10.006_bib0060","article-title":"Chapter 5: updating the natural history of HPV and anogenital cancer","volume":"24","author":"Moscicki","year":"2006","journal-title":"Vaccine"},{"issue":"Suppl. 5","key":"10.1016\/j.canep.2015.10.006_bib0065","doi-asserted-by":"crossref","first-page":"F24","DOI":"10.1016\/j.vaccine.2012.05.089","article-title":"Updating the natural history of human papillomavirus and anogenital cancers","volume":"30","author":"Moscicki","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.canep.2015.10.006_bib0070","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/ijc.21493","article-title":"Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies","volume":"118","author":"Appleby","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canep.2015.10.006_bib0075","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/S0140-6736(07)61684-5","article-title":"Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies","volume":"370","author":"Appleby","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.canep.2015.10.006_bib0080","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/ijc.28665","article-title":"Prospective seroepidemiologic study on the role of Human Papillomavirus and other infections in cervical carcinogenesis: evidence from the EPIC cohort","volume":"135","author":"Castellsague","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canep.2015.10.006_bib0085","first-page":"1","volume":"vol. 10","author":"IARC","year":"2005"},{"key":"10.1016\/j.canep.2015.10.006_bib0090","series-title":"GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]","author":"Ferlay","year":"2013"},{"issue":"Suppl. 5","key":"10.1016\/j.canep.2015.10.006_bib0095","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A review of clinical trials of human papillomavirus prophylactic vaccines","volume":"30","author":"Schiller","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.canep.2015.10.006_bib0100","first-page":"118","article-title":"Human papillomavirus vaccines","volume":"84","author":"World Health Organization","year":"2009","journal-title":"WHO Position Paper, Wkly Epidemiol Rec."},{"key":"10.1016\/j.canep.2015.10.006_bib0105","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jadohealth.2007.02.015","article-title":"Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant","volume":"40","author":"Pedersen","year":"2007","journal-title":"J. Adolesc. Health"},{"key":"10.1016\/j.canep.2015.10.006_bib0110","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1542\/peds.2006-0461","article-title":"Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women","volume":"118","author":"Block","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.canep.2015.10.006_bib0115","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/ijc.23260","article-title":"Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women","volume":"122","author":"Perez","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canep.2015.10.006_bib0120","first-page":"465","article-title":"Human papillomavirus vaccines: WHO position paper, October 2014","volume":"89","author":"World Health Organization","year":"2014","journal-title":"Wkly. Epidemiol. Rec."},{"key":"10.1016\/j.canep.2015.10.006_bib0125","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2334-11-13","article-title":"Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis","volume":"11","author":"Lu","year":"2011","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.canep.2015.10.006_bib0130","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1473-3099(12)70187-1","article-title":"Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis","volume":"12","author":"Malagon","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.canep.2015.10.006_bib0135","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jadohealth.2008.10.002","article-title":"Immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine in healthy boys aged 10\u201318 years","volume":"44","author":"Petaja","year":"2009","journal-title":"J. Adolesc. Health"},{"key":"10.1016\/j.canep.2015.10.006_bib0140","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canep.2015.10.006_bib0145","doi-asserted-by":"crossref","first-page":"768","DOI":"10.4161\/hv.7.7.15579","article-title":"Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults","volume":"7","author":"Moreira","year":"2011","journal-title":"Hum. Vaccine"},{"key":"10.1016\/j.canep.2015.10.006_bib0150","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canep.2015.10.006_bib0155","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1128\/CVI.05208-11","article-title":"Immunogenicity of the quadrivalent human papillomavirus (type 6\/11\/16\/18) vaccine in males 16 to 26 years old","volume":"19","author":"Hillman","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.canep.2015.10.006_bib0160","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1016\/j.vaccine.2013.06.057","article-title":"Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males","volume":"31","author":"Goldstone","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.canep.2015.10.006_bib0165","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1940-6207.CAPR-09-0031","article-title":"A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6\/11\/16\/18) vaccine against high-grade cervical and external genital lesions","volume":"2","author":"Kjaer","year":"2009","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"10.1016\/j.canep.2015.10.006_bib0170","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women","volume":"102","author":"Munoz","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canep.2015.10.006_bib0175","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2159-8290.CD-11-0131","article-title":"Prevention of persistent human papillomavirus infection by an HPV16\/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica","volume":"1","author":"Herrero","year":"2011","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canep.2015.10.006_bib0180","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canep.2015.10.006_bib0185","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/aje\/kwt047","article-title":"Impact of human papillomavirus vaccination on cervical cytology screening, colposcopy, and treatment","volume":"178","author":"Rodriguez","year":"2013","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.canep.2015.10.006_bib0190","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s40265-014-0255-z","article-title":"Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil((R))): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts","volume":"74","author":"McCormack","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.canep.2015.10.006_bib0195","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bjc.2011.185","article-title":"End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24\u201345 years of age","volume":"105","author":"Castellsague","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canep.2015.10.006_bib0200","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(14)60920-X","article-title":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study","volume":"384","author":"Skinner","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.canep.2015.10.006_bib0205","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S1470-2045(11)70213-3","article-title":"Efficacy of a bivalent HPV 16\/18 vaccine against anal HPV 16\/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial","volume":"12","author":"Kreimer","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canep.2015.10.006_bib0210","doi-asserted-by":"crossref","first-page":"e68329","DOI":"10.1371\/journal.pone.0068329","article-title":"Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica","volume":"8","author":"Herrero","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.canep.2015.10.006_bib0215","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1093\/infdis\/jiu357","article-title":"Reduced prevalence of vulvar HPV16\/18 infection among women who received the HPV16\/18 bivalent vaccine: a nested analysis within the Costa Rica vaccine trial","volume":"210","author":"Lang Kuhs","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.canep.2015.10.006_bib0220","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.canep.2015.10.006_bib0225","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1086\/597309","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years","volume":"199","author":"Wheeler","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.canep.2015.10.006_bib0230","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40264-013-0039-5","article-title":"Safety of human papillomavirus vaccines: a review","volume":"36","author":"Macartney","year":"2013","journal-title":"Drug Safety"},{"key":"10.1016\/j.canep.2015.10.006_bib0235","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/INF.0b013e3181b77906","article-title":"Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine","volume":"29","author":"Block","year":"2010","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.canep.2015.10.006_bib0240","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/pds.3554","article-title":"Pooled analysis of large and long-term safety data from the human papillomavirus-16\/18-AS04-adjuvanted vaccine clinical trial programme","volume":"23","author":"Angelo","year":"2014","journal-title":"Pharmacoepidemiol. Drug Safety"},{"key":"10.1016\/j.canep.2015.10.006_bib0245","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.biologicals.2012.07.007","article-title":"Current status and future directions of post-marketing vaccine safety monitoring with focus on USA and Europe","volume":"40","author":"Bonhoeffer","year":"2012","journal-title":"Biologicals"},{"key":"10.1016\/j.canep.2015.10.006_bib0250","series-title":"Yellow Card Scheme","year":"2014"},{"key":"10.1016\/j.canep.2015.10.006_bib0255","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/pds.3593","article-title":"Post-licensure safety surveillance for human papillomavirus-16\/18-AS04-adjuvanted vaccine: more than 4 years of experience","volume":"23","author":"Angelo","year":"2014","journal-title":"Pharmacoepidemiol. Drug Safety"},{"key":"10.1016\/j.canep.2015.10.006_bib0260","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/jama.2009.1201","article-title":"Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine","volume":"302","author":"Slade","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.canep.2015.10.006_bib0265","series-title":"Adverse Effects of Vaccines: Evidence and Causality","year":"2011"},{"key":"10.1016\/j.canep.2015.10.006_bib0270","series-title":"Statement on the Continued Safety of HPV Vaccination","year":"2014"},{"key":"10.1016\/j.canep.2015.10.006_bib0275","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.medmal.2014.07.005","article-title":"[HPV vaccination is still difficult to implement]","volume":"44","author":"Gaudelus","year":"2014","journal-title":"Med. Mal. Infect."},{"key":"10.1016\/j.canep.2015.10.006_bib0280","doi-asserted-by":"crossref","first-page":"e657","DOI":"10.1542\/peds.2013-4144","article-title":"Long-term study of a quadrivalent human papillomavirus vaccine","volume":"134","author":"Ferris","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.canep.2015.10.006_bib0285","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/infdis\/jis590","article-title":"Fall in human papillomavirus prevalence following a national vaccination program","volume":"206","author":"Tabrizi","year":"2012","journal-title":"J. Infect. Dis"},{"key":"10.1016\/j.canep.2015.10.006_bib0290","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/sextrans-2011-050234","article-title":"The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme","volume":"87","author":"Read","year":"2011","journal-title":"Sex Transm. Infect."},{"key":"10.1016\/j.canep.2015.10.006_bib0295","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/S0140-6736(11)60551-5","article-title":"Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study","volume":"377","author":"Brotherton","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.canep.2015.10.006_bib0300","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/jnci\/djt032","article-title":"Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study","volume":"105","author":"Leval","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canep.2015.10.006_bib0305","series-title":"Human Papillomavirus 9-valent Vaccine (Gardasil 9)","year":"2015"},{"key":"10.1016\/j.canep.2015.10.006_bib0310","series-title":"Summary of the European Public Assessment Report (EPAR) for Gardasil 9","author":"European Medicines Agency (EMA)","year":"2015"},{"key":"10.1016\/j.canep.2015.10.006_bib0315","series-title":"European Guidelines for Quality Assurance in Cervical Cancer Screening","year":"2015"},{"key":"10.1016\/j.canep.2015.10.006_bib0320","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/jnci\/djr319","article-title":"Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine","volume":"103","author":"Kreimer","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canep.2015.10.006_bib0325","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.vaccine.2013.11.059","article-title":"Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16\/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months","volume":"32","author":"Lazcano-Ponce","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.canep.2015.10.006_bib0330","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.canep.2015.10.006_bib0335","article-title":"HPV vaccines: systematic review of literature on alternative vaccination schedules, in: Evidence-based recommendations on human papillomavirus (HPV) schedules: Background paper for SAGE discussions","author":"D\u2019Addario","year":"2014","journal-title":"World Health Organization, Geneva"},{"key":"10.1016\/j.canep.2015.10.006_bib0340","series-title":"European Guidelines for Quality Assurance in Cervical Cancer Screening","article-title":"Implementation of vaccination against human papillomavirus in Europe (S3)","author":"De Vuyst","year":"2015"},{"key":"10.1016\/j.canep.2015.10.006_bib0345","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.vaccine.2015.02.028","article-title":"Organization and quality of HPV vaccination programs in Europe","volume":"33","author":"Elfstrom","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.canep.2015.10.006_bib0350","first-page":"53","article-title":"Evaluation of human papilloma virus (HPV) vaccination strategies and vaccination coverage in adolescent girls worldwide","volume":"69","author":"Owsianka","year":"2015","journal-title":"Przegl. Epidemiol."},{"key":"10.1016\/j.canep.2015.10.006_bib0355","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1750-9378-9-4","article-title":"Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model","volume":"9","author":"Baussano","year":"2014","journal-title":"Infect. Agent Cancer"},{"key":"10.1016\/j.canep.2015.10.006_bib0360","series-title":"Summary of the European Public Assessment Report (EPAR) for Cervarix","year":"2015"},{"key":"10.1016\/j.canep.2015.10.006_bib0365","series-title":"Summary of the European Public Assessment Report (EPAR) for Gardasil","year":"2015"},{"key":"10.1016\/j.canep.2015.10.006_bib0370","series-title":"Introduction of HPV Vaccines in EU countries \u2013 An Update","year":"2012"},{"key":"10.1016\/j.canep.2015.10.006_bib0375","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/infdis\/jir281","article-title":"Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses","volume":"204","author":"Westra","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.canep.2015.10.006_bib0380","first-page":"428","article-title":"Atypical squamous cells of undetermined significance in patients with HPV positive DNA testing and correlation with disease progression by age group: an institutional experience","volume":"5","author":"Rodriguez","year":"2012","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.canep.2015.10.006_bib0385","series-title":"November 2011 PBAC Meeting Outcomes \u2013 Positive Recommendations","year":"2011"},{"key":"10.1016\/j.canep.2015.10.006_bib0390","volume":"vol. 38","year":"2012"},{"key":"10.1016\/j.canep.2015.10.006_bib0395","series-title":"Human Papillomavirus Vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","year":"2014"},{"key":"10.1016\/j.canep.2015.10.006_bib0400","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1002\/ijc.29082","article-title":"EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection","volume":"136","author":"Giuliano","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canep.2015.10.006_bib0405","series-title":"The European Code Against Cancer (ECAC)","year":"2014"},{"key":"10.1016\/j.canep.2015.10.006_bib0410","series-title":"World Cancer Report 2014, International Agency for Research on Cancer","first-page":"105","article-title":"Infections","author":"Franceschi","year":"2014"},{"key":"10.1016\/j.canep.2015.10.006_bib0415","series-title":"World Cancer Report 2014","first-page":"105","article-title":"Liver cancer","author":"Theise","year":"2014"},{"key":"10.1016\/j.canep.2015.10.006_bib0420","series-title":"Cancer","article-title":"Liver Cancer","author":"Chen","year":"2014"},{"key":"10.1016\/j.canep.2015.10.006_bib0425","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of viral hepatitis and hepatocellular carcinoma","volume":"142","author":"El-Serag","year":"2012","journal-title":"Gastroenterology"},{"issue":"807351","key":"10.1016\/j.canep.2015.10.006_bib0430","article-title":"Pathogenetic mechanisms of hepatitis C virus-induced B-cell lymphomagenesis","volume":"2012","author":"Forghieri","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.canep.2015.10.006_bib0435","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/ijc.21903","article-title":"The burden of cancer attributable to alcohol drinking","volume":"119","author":"Boffetta","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canep.2015.10.006_bib0440","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/sj.bjc.6603649","article-title":"Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review","volume":"96","author":"Raza","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canep.2015.10.006_bib0445","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/1471-2334-13-181","article-title":"Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening","volume":"13","author":"Hahne","year":"2013","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.canep.2015.10.006_bib0450","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1017\/S0950268813000940","article-title":"Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association","volume":"142","author":"Hope","year":"2014","journal-title":"Epidemiol. Infect."},{"key":"10.1016\/j.canep.2015.10.006_bib0455","series-title":"Assessing the Burden of Key Infectious Diseases Affecting Migrant Populations in the EU\/EEA","author":"European Centre for Disease Prevention and Control","year":"2014"},{"issue":"Suppl. 2","key":"10.1016\/j.canep.2015.10.006_bib0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jvh.12120","article-title":"The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conference","volume":"20","author":"Hatzakis","year":"2013","journal-title":"J. Viral. Hepat."},{"key":"10.1016\/j.canep.2015.10.006_bib0465","doi-asserted-by":"crossref","first-page":"11630","DOI":"10.3748\/wjg.v20.i33.11630","article-title":"Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis","volume":"20","author":"Tarocchi","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.canep.2015.10.006_bib0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","author":"Gower","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canep.2015.10.006_bib0475","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrc3449","article-title":"Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma","volume":"13","author":"Arzumanyan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canep.2015.10.006_bib0480","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2000-9505","article-title":"Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome","volume":"20","author":"Alter","year":"2000","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.canep.2015.10.006_bib0485","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.kjms.2011.10.020","article-title":"Chronic hepatitis C infection in the elderly","volume":"27","author":"Huang","year":"2011","journal-title":"Kaohsiung J. Med. Sci."},{"key":"10.1016\/j.canep.2015.10.006_bib0490","first-page":"405","article-title":"Hepatitis B vaccines. Position paper","volume":"40","author":"World Health Organization","year":"2009","journal-title":"Weekly Epidemiol. Rec."},{"key":"10.1016\/j.canep.2015.10.006_bib0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1651-2227.2010.01823.x","article-title":"Vaccination of children\u2013a systematic review","volume":"99","author":"Ortqvist","year":"2010","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.canep.2015.10.006_bib0500","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006481.pub2","article-title":"Hepatitis B immunisation in persons not previously exposed to hepatitis B or with unknown exposure status","author":"Mathew","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.canep.2015.10.006_bib0505","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.1016\/j.vaccine.2010.06.111","article-title":"Factors associated with effectiveness of the first dose of hepatitis B vaccine in China: 1992\u20132005","volume":"28","author":"Cui","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.canep.2015.10.006_bib0510","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jhep.2012.05.021","article-title":"Minimization of hepatitis B infection by a 25-year universal vaccination program","volume":"57","author":"Ni","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canep.2015.10.006_bib0515","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jama.2013.276701","article-title":"Thirty-year outcomes of the national hepatitis B immunization program in Taiwan","volume":"310","author":"Chiang","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.canep.2015.10.006_bib0520","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/carcin\/bgt007","article-title":"Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China","volume":"34","author":"Sun","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canep.2015.10.006_bib0525","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10552-010-9721-4","article-title":"Reduction of hepatocellular carcinoma in childhood after introduction of selective vaccination against hepatitis B virus for infants born to HBV carrier mothers","volume":"22","author":"Tajiri","year":"2011","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.canep.2015.10.006_bib0530","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/hep.24442","article-title":"Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program","volume":"54","author":"McMahon","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.canep.2015.10.006_bib0535","first-page":"5782","article-title":"The Gambia Hepatitis Intervention Study","volume":"47","author":"The Gambia Hepatitis Study Group","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.canep.2015.10.006_bib0540","doi-asserted-by":"crossref","first-page":"e58029","DOI":"10.1371\/journal.pone.0058029","article-title":"Observational study of vaccine efficacy 24 years after the start of hepatitis B vaccination in two Gambian villages: no need for a booster dose","volume":"8","author":"Mendy","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.canep.2015.10.006_bib0545","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1158\/1055-9965.EPI-08-0303","article-title":"20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer","volume":"17","author":"Viviani","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"10.1016\/j.canep.2015.10.006_bib0550","first-page":"313","article-title":"Design and compliance of HBV vaccination trial on newborns to prevent hepatocellular carcinoma and 5-year results of its pilot study","volume":"15","author":"Sun","year":"1991","journal-title":"Cancer Detect. Prev."},{"key":"10.1016\/j.canep.2015.10.006_bib0555","doi-asserted-by":"crossref","first-page":"e1001774","DOI":"10.1371\/journal.pmed.1001774","article-title":"Efficacy of neonatal HBV Vaccination on liver cancer and other liver diseases over 30-Year Follow-up of the Qidong Hepatitis B intervention study: a cluster randomized controlled trial","volume":"11","author":"Qu","year":"2014","journal-title":"PLoS Med."},{"key":"10.1016\/j.canep.2015.10.006_bib0560","series-title":"The Childhood Immunization Schedule and Safety: Stakeholder Concerns, Scientific Evidence, and Future Studies","year":"2013"},{"key":"10.1016\/j.canep.2015.10.006_bib0565","series-title":"Hepatitis B Vaccination in Europe November 2008\u2013March 2009 (VENICE project)","author":"O\u2019Flanagan","year":"2009"},{"key":"10.1016\/j.canep.2015.10.006_bib0570","series-title":"Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection","year":"2014"},{"key":"10.1016\/j.canep.2015.10.006_bib0575","series-title":"Hepatitis B and C Testing: People at Risk of Infection, NICE Guidelines [PH43]","year":"2012"},{"key":"10.1016\/j.canep.2015.10.006_bib0580","series-title":"Hepatitis B (chronic): Diagnosis and Management, NICE Guidelines [CG165]","year":"2013"},{"key":"10.1016\/j.canep.2015.10.006_bib0585","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canep.2015.10.006_bib0590","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jhep.2014.05.001","article-title":"EASL recommendations on treatment of hepatitis C","volume":"61","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canep.2015.10.006_bib0595","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/M14-1018","article-title":"Screening for hepatitis B virus infection in nonpregnant adolescents and adults: U.S. Preventive Services Task Force recommendation statement","volume":"161","author":"LeFevre","year":"2014","journal-title":"Ann. Int. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.canep.2015.10.006_bib0600","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/liv.12057","article-title":"Impact of therapy on the outcome of chronic hepatitis B","volume":"33","author":"Liaw","year":"2013","journal-title":"Liver Int."},{"key":"10.1016\/j.canep.2015.10.006_bib0605","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cgh.2010.11.040","article-title":"Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B","volume":"9","author":"Schiff","year":"2011","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.canep.2015.10.006_bib0610","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.canep.2015.10.006_bib0615","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.23785","article-title":"Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B","volume":"52","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.canep.2015.10.006_bib0620","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1365-2036.2010.04447.x","article-title":"Meta-analysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B","volume":"32","author":"Wong","year":"2010","journal-title":"Aliment Pharmacol. Ther."},{"key":"10.1016\/j.canep.2015.10.006_bib0625","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1872-034X.2011.00801.x","article-title":"Long-term effect of interferon treatment on the progression of chronic hepatitis B: Bayesian meta-analysis and meta-regression","volume":"41","author":"Jin","year":"2011","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.canep.2015.10.006_bib0630","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1586\/egh.12.52","article-title":"Considerations for the long-term treatment of chronic hepatitis B with nucleos(t) ide analogs","volume":"6","author":"Petersen","year":"2012","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.canep.2015.10.006_bib0635","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/hep.26317","article-title":"Does hepatitis B treatment reduce the incidence of hepatocellular carcinoma?","volume":"58","author":"Sherman","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.canep.2015.10.006_bib0640","doi-asserted-by":"crossref","first-page":"175","DOI":"10.4292\/wjgpt.v5.i3.175","article-title":"Prevention of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"5","author":"Fernandez-Rodriguez","year":"2014","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"key":"10.1016\/j.canep.2015.10.006_bib0645","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001313","article-title":"Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials","volume":"2","author":"Kimer","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.canep.2015.10.006_bib0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2009.11.018","article-title":"A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus","volume":"8","author":"Singal","year":"2010","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.canep.2015.10.006_bib0655","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.canep.2015.10.006_bib0660","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies","volume":"158","author":"Morgan","year":"2013","journal-title":"Ann. Int. Med."},{"key":"10.1016\/j.canep.2015.10.006_bib0665","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/hep.26641","article-title":"Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study","volume":"58","author":"Fried","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.canep.2015.10.006_bib0670","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","article-title":"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"384","author":"Jacobson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.canep.2015.10.006_bib0675","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","article-title":"Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.canep.2015.10.006_bib0680","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1053\/j.gastro.2014.02.051","article-title":"Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial","volume":"146","author":"Forns","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canep.2015.10.006_bib0685","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2013.10.058","article-title":"Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial","volume":"146","author":"Zeuzem","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canep.2015.10.006_bib0690","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canep.2015.10.006_bib0695","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canep.2015.10.006_bib0700","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canep.2015.10.006_bib0705","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jhep.2013.03.030","article-title":"NS5A inhibitors in the treatment of hepatitis C","volume":"59","author":"Pawlotsky","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canep.2015.10.006_bib0710","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canep.2015.10.006_bib0715","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canep.2015.10.006_bib0720","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10198-014-0653-x","article-title":"Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness?","volume":"16","author":"van de Vooren","year":"2015","journal-title":"Eur. J. Health. Econ."},{"key":"10.1016\/j.canep.2015.10.006_bib0725","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/ijc.28999","article-title":"Global burden of gastric cancer attributable to Helicobacter pylori","volume":"136","author":"Plummer","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canep.2015.10.006_bib0730","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/hel.12061","article-title":"Sociodemographic determinants of prevalence and incidence of Helicobacter pylori infection in Portuguese adults","volume":"18","author":"Bastos","year":"2013","journal-title":"Helicobacter"},{"key":"10.1016\/j.canep.2015.10.006_bib0735","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1136\/gut.2007.145177","article-title":"Gastro-oesophageal reflux symptoms, oesophagitis and Barrett\u2019s oesophagus in the general population: the Loiano\u2013Monghidoro study","volume":"57","author":"Zagari","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.canep.2015.10.006_bib0740","series-title":"Helicobacter pylori in Developing Countries","author":"World Gastroenterology Organisation Global Guidelines","year":"2010"},{"key":"10.1016\/j.canep.2015.10.006_bib0745","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/ije\/31.3.624","article-title":"Relation of adult lifestyle and socioeconomic factors to the prevalence of Helicobacter pylori infection","volume":"31","author":"Moayyedi","year":"2002","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.canep.2015.10.006_bib0750","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10552-012-0117-5","article-title":"Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701)","volume":"24","author":"Porras","year":"2013","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.canep.2015.10.006_bib0755","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1523-5378.2007.00504.x","article-title":"Seroprevalence of Helicobacter pylori in South Korea","volume":"12","author":"Yim","year":"2007","journal-title":"Helicobacter"},{"key":"10.1016\/j.canep.2015.10.006_bib0760","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1083-4389.2004.00229.x","article-title":"Helicobacter pylori infection in children in Estonia: decreasing seroprevalence during the 11-year period of profound socioeconomic changes","volume":"9","author":"Oona","year":"2004","journal-title":"Helicobacter"},{"key":"10.1016\/j.canep.2015.10.006_bib0765","series-title":"Helicobacter pylori eradication as a strategy for preventing gastric cancer","first-page":"64","article-title":"Effectiveness of Helicobacter pylori eradication","author":"Greenberg","year":"2014"},{"key":"10.1016\/j.canep.2015.10.006_bib0770","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/jnci\/djs003","article-title":"Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality","volume":"104","author":"Ma","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canep.2015.10.006_bib0775","doi-asserted-by":"crossref","first-page":"g3174","DOI":"10.1136\/bmj.g3174","article-title":"Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials","volume":"348","author":"Ford","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.canep.2015.10.006_bib0780","series-title":"Helicobacter pylori eradication as a strategy for preventing gastric cancer","first-page":"95","article-title":"Potential regimens for the mass eradication of Helicobacter pylori infection","author":"Gisbert","year":"2014"},{"key":"10.1016\/j.canep.2015.10.006_bib0785","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/gutjnl-2012-302084","article-title":"Management of Helicobacter pylori infection\u2013the Maastricht IV\/Florence Consensus Report","volume":"61","author":"Malfertheiner","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.canep.2015.10.006_bib0790","series-title":"Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer","year":"2014"},{"key":"10.1016\/j.canep.2015.10.006_bib0795","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/sj.bjc.6605756","article-title":"Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study","volume":"103","author":"Franceschi","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canep.2015.10.006_bib0800","series-title":"2012-UNAIDS Report on the Global AIDS Epidemic","year":"2012"},{"key":"10.1016\/j.canep.2015.10.006_bib0805","series-title":"HIV\/AIDS Surveillance in Europe 2013","year":"2014"},{"key":"10.1016\/j.canep.2015.10.006_bib0810","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/aje\/kwt151","article-title":"Clifford et al. respond to biological and clinical insights from epidemiologic research into HIV, HPV, and anal cancer","volume":"178","author":"Clifford","year":"2013","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.canep.2015.10.006_bib0815","doi-asserted-by":"crossref","first-page":"706","DOI":"10.7326\/0003-4819-157-10-201211200-00007","article-title":"Screening for HIV: systematic review to update the 2005 U.S. Preventive Services Task Force recommendation","volume":"157","author":"Chou","year":"2012","journal-title":"Ann. Int. Med."},{"key":"10.1016\/j.canep.2015.10.006_bib0820","series-title":"Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach","year":"2013"},{"key":"10.1016\/j.canep.2015.10.006_bib0825","series-title":"Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents","year":"2015"},{"key":"10.1016\/j.canep.2015.10.006_bib0830","series-title":"Guide for HIV\/AIDS Clinical Care\u20132014 Edition","year":"2014"},{"key":"10.1016\/j.canep.2015.10.006_bib0835","doi-asserted-by":"crossref","first-page":"51","DOI":"10.7326\/0003-4819-159-1-201307020-00645","article-title":"Screening for HIV: U.S. Preventive Services Task Force Recommendation Statement","volume":"159","author":"Moyer","year":"2013","journal-title":"Ann. Int. Med."}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782115002179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782115002179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T03:27:24Z","timestamp":1589599644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782115002179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":167,"alternative-id":["S1877782115002179"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2015.10.006","relation":{},"ISSN":["1877-7821"],"issn-type":[{"value":"1877-7821","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European Code against Cancer 4th Edition: Infections and Cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canep.2015.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}